Fulcrum Therapeutics (FULC) Assets Average (2019 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Assets Average of $335.4 million for Q2 2026, up 42.26% year-over-year from $235.7 million in Q2 2025, and down 5.94% quarter-over-quarter from $356.5 million in Q1 2026.
Fulcrum Therapeutics (FULC) Assets Average (2019 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Assets Average for 8 consecutive years, with $335.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets Average rose 42.26% year-over-year to $335.4 million; the TTM figure through Jun 2026 stood at $335.4 million (up 42.26% YoY), while the FY2025 annual figure was $313.5 million, up 20.95% from the prior year.
- Assets Average declined to $335.4 million in Q2 2026 per FULC's latest filing, from $356.5 million in the prior quarter.
- Across five years, Assets Average topped out at $356.5 million in Q1 2026 and bottomed at $207.7 million in Q2 2022.
- Historically, Assets Average has averaged $266.3 million across 5 years, with a median of $265.9 million in 2023.
- Annual changes were most pronounced in 2022 — Assets Average surged 59.15% — and 2025, when it retreated 22.6%.
- Fulcrum Therapeutics' Assets Average stood at $237.2 million in 2022, then gained by 13.08% to $268.3 million in 2023, then grew by 0.59% to $269.9 million in 2024, then grew by 7.67% to $290.6 million in 2025, then rose by 15.41% to $335.4 million in 2026.
- Business Quant data shows FULC's Assets Average at $335.4 million in Q2 2026, $356.5 million in Q1 2026, and $290.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | 335.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 335.36 Mn |
| Mar 31, 2026 | 356.53 Mn |
| Dec 31, 2025 | 290.57 Mn |
| Sep 30, 2025 | 221.85 Mn |
| Jun 30, 2025 | 235.74 Mn |
| Mar 31, 2025 | 251.68 Mn |
| Dec 31, 2024 | 269.86 Mn |
| Sep 30, 2024 | 286.63 Mn |
| Jun 30, 2024 | 263.42 Mn |
| Mar 31, 2024 | 245.14 Mn |
| Dec 31, 2023 | 268.29 Mn |
| Sep 30, 2023 | 289.61 Mn |
| Jun 30, 2023 | 310.73 Mn |
| Mar 31, 2023 | 273.90 Mn |
| Dec 31, 2022 | 237.25 Mn |
| Sep 30, 2022 | 221.52 Mn |
| Jun 30, 2022 | 207.74 Mn |
| Mar 31, 2022 | 227.62 Mn |
| Dec 31, 2021 | 245.27 Mn |
| Sep 30, 2021 | 196.71 Mn |